SOURCE: Xtalks

Xtalks Webinars

June 15, 2016 07:00 ET

Fecal Matters: Clinical Impact and Cost Effectiveness of Molecular GI Pathogen Testing

TORONTO, ON--(Marketwired - June 15, 2016) - Nanosphere and Xtalks will host a complimentary, P.A.C.E. accredited webinar on Wednesday, June 29, 2016, featuring Amanda Harrington, Director of Clinical Microbiology and Assistant Professor of Pathology at University of Illinois at Chicago, and Jose Alexander, Microbiology Supervisor at Marin General Hospital in Greenbrae, California, as the presenters.

Diarrhea caused by bacterial, viral, and/or parasitic infection represents a significant worldwide healthcare burden. Each year, there are two billion instances of diarrheal disease globally, resulting in nearly two million deaths.1 The World Health Organization estimates that diarrhea is the cause of or is a major contributor to approximately one-quarter of all post-neonatal childhood deaths.2 In the United States, an estimated 1.4 episodes of acute diarrhea occur per person each year.3 Though most cases of diarrheal disease are generally self-resolving and not life-threatening in immunocompetent individuals, certain bacterial and viral infections can result in serious clinical morbidity and even death.

The current diagnostic challenge associated with detection of community-acquired diarrhea is twofold. Since clinical presentation of diarrheal disease does not narrow down the potentially responsible pathogen(s), physicians often end up taking the "shotgun" approach to diagnostic testing by ordering testing for a majority of stool pathogens. If physicians are able to characterize the patient's history, it could greatly narrow the number of diagnostic tests necessary for a given patient. On the diagnostic end, stool culture and ova and parasite (O&P) remain the gold standard diagnostics. Though generally considered sensitive and specific, these procedures are labor-intensive, unpleasant for technicians, can take as long as 5-7 days to produce definitive results in the case of stool cultures, and require a high degree of technical skill in the case of performing O&Ps. Together, the excessive ordering of stool pathogen testing by physicians paired with less-than-ideal diagnostic options has led to what some consider significant inefficiencies in the clinical laboratory. As a result, medical technologists can spend unnecessary time working up negative stools, which can account for upwards of 95% of stools samples submitted for testing.

Rapid diagnostics for stool pathogens have only recently emerged as viable options for testing for community-acquired diarrhea. Multiplex molecular methods are very well suited as the diagnostic platform for stool pathogens as these tests can target a majority of stool pathogens at one time. The sample-to-results automation and rapid turnaround times of these tests will result in improved workflow efficiencies in the clinical laboratory. The improved sensitivity of molecular-based tests over culture will also provide the accurate results necessary for earlier optimization of patient management, better infection control, and quicker public health response to potential outbreaks.

Diarrheal illness will continue to be a burden to healthcare providers worldwide. Rapid diagnostic tests for stool pathogens may provide a means to minimize the impact of this burden throughout the entire hospital.

To learn more about this event, visit: Fecal Matters: Clinical Impact and Cost Effectiveness of Molecular GI Pathogen Testing

P.A.C.E. Accreditation

Xtalks is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program - Attendees will receive further details after the event.

About Nanosphere

Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, optimal patient treatment and improved healthcare economics. The Company's versatile technology platform, the Verigene System, enables clinicians to rapidly detect the most complex, costly and deadly infectious diseases through a low cost and simple-to-use multiplex molecular diagnostic test. The combination of this innovative technology and Nanosphere's customer-driven solutions keeps commitment to the patient at the forefront of its business.

For more information visit www.nanosphere.us

About Xtalks

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx

1. World Health Organization. Diarrhoeal Disease: Fact Sheet N°330 April 2013.http://www.who.int/mediacentre/factsheets/fs330/en/index.html. Accessed 17 February 2014.
2. Bryce J, Boschi-Pinto C, Shibuya K, Black RE. WHO Estimates of the Causes of Death in Children. Lancet 2005; 365: 1147-1152.
3. Herikstad H, Yang S, Van Gilder TJ, Vugia D, Hadler J, Blake P, Deneen V, Shiferaw B, Angulo FJ. A Population-Based Estimate of the Burden of Diarrhoeal Illness in the Unites States: FoodNet, 1996-1997. Epidemiol Infect 2002; 129: 9-17.

Image Available: http://www.marketwire.com/library/MwGo/2016/6/13/11G102696/Images/Nano_logo_300-1125224536675.jpg
Image Available: http://www.marketwire.com/library/MwGo/2016/6/13/11G102696/Images/PACE_Logo-1163389360782.jpg

Contact Information